Behavioral phenotypes in schizophrenic animal models with multiple combinations of genetic and environmental factors

Journal of Pharmacological Sciences

Volumn 121, Issue 3, 2013, Pages 185-191

  Hida, Hirotake ^a   Mouri, Akihiro ^a   Noda, Yukihiro ^a  

^a MEIJO UNIVERSITY   (Japan)

Author keywords

Animal model; Behavioral phenotype; Environment environment interaction; Gene environment interaction; Schizophrenia

Indexed keywords

CLOZAPINE; DISRUPTED IN SCHIZOPHRENIA 1 PROTEIN; HALOPERIDOL; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR 1; NEU DIFFERENTIATION FACTOR; NUCLEAR RECEPTOR RELATED FACTOR 1; PHENCYCLIDINE; TRANSCRIPTION FACTOR PITX3; TYROSINE 3 MONOOXYGENASE;

BEHAVIOR CHANGE; CENTRAL NERVOUS SYSTEM INFECTION; DISC1 GENE; DRUG ABUSE; DRUG EFFECT; ENVIRONMENTAL FACTOR; GENETIC SUSCEPTIBILITY; GENOTYPE ENVIRONMENT INTERACTION; HEREDITY; HYPERACTIVITY; IMMUNOMODULATION; MUTANT; NONHUMAN; NRG1 GENE; NURR1 GENE; PACAP GENE; PATHOGENESIS; PATHOPHYSIOLOGY; PHENOTYPE; POINT MUTATION; REVIEW; SCHIZOPHRENIA; SENSORY GATING; SOCIAL STRESS; TRANSGENE;

EID: 84877289899     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.12R15CP     Document Type: Review

References (32)

1. Rossler W, Salize HJ, van Os J, Riecher-Rossler A. Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol. 2005;15:399-409. (Pubitemid 40943544)
2. McDonald C, Murray RM. Early and late environmental risk factors for schizophrenia. Brain Res Brain Res Rev. 2000;31: 130-137. (Pubitemid 30136169)
3. Bayer TA, Falkai P, Maier W. Genetic and non-genetic vulnerability factors in schizophrenia: the basis of the "two hit hypothesis". J Psychiatr Res. 1999;33:543-548.
4. Ayhan Y, Sawa A, Ross CA, Pletnikov MV. Animal models of gene-environment interactions in schizophrenia. Behav Brain Res. 2009;204:274-281.
5. Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry. 2005;10:40-68. (Pubitemid 40139588)
6. Hikida T, Jaaro-Peled H, Seshadri S, Oishi K, Hookway C, Kong S, et al. Dominant-negative DISC1 transgenic mice display schizophrenia-Associated phenotypes detected by measures translatable to humans. Proc Natl Acad Sci U S A. 2007;104: 14501-14506. (Pubitemid 350003290)
7. Ibi D, Nagai T, Koike H, Kitahara Y, Mizoguchi H, Niwa M, et al. Combined effect of neonatal immune activation and mutant DISC1 on phenotypic changes in adulthood. Behav Brain Res. 2010;206:32-37.
8. Takeuchi O, Akira S. Recognition of viruses by innate immunity. Immunol Rev. 2007;220:214-224. (Pubitemid 350045565)
9. Ibi D, Nagai T, Kitahara Y, Mizoguchi H, Koike H, Shiraki A, et al. Neonatal polyI:C treatment in mice results in schizophrenialike behavioral and neurochemical abnormalities in adulthood. Neurosci Res. 2009;64:297-305.
10. Nagai T, Kitahara Y, Ibi D, Nabeshima T, Sawa A, Yamada K. Effects of antipsychotics on the behavioral deficits in human dominant-negative DISC1 transgenic mice with neonatal polyI:C treatment. Behav Brain Res. 2011;225:305-310.
11. Abazyan B, Nomura J, Kannan G, Ishizuka K, Tamashiro KL, Nucifora F, et al. Prenatal interaction of mutant DISC1 and immune activation produces adult psychopathology. Biol Psychiatry. 2010;68:1172-1181.
12. Millar JK, Mackie S, Clapcote SJ, Murdoch H, Pickard BS, Christie S, et al. Disrupted in schizophrenia 1 and phosphodiesterase 4B: towards an understanding of psychiatric illness. J Physiol. 2007;584:401-405. (Pubitemid 47578327)
13. Clapcote SJ, Lipina TV, Millar JK, Mackie S, Christie S, Ogawa F, et al. Behavioral phenotypes of Disc1 missense mutations in mice. Neuron. 2007;54:387-402. (Pubitemid 46671409)
14. Tessner KD, Mittal V, Walker EF. Longitudinal study of stressful life events and daily stressors among adolescents at high risk for psychotic disorders. Schizophr Bull. 2011;37:432-441.
15. Selten JP, Cantor-Graae E. Social defeat: risk factor for schizophrenia? Br J Psychiatry. 2005;187:101-102. (Pubitemid 41139679)
16. Miczek KA, Yap JJ, Covington HE 3rd. Social stress, therapeutics and drug abuse: preclinical models of escalated and depressed intake. Pharmacol Ther. 2008;120:102-128.
17. Haque FN, Lipina TV, Roder JC, Wong AH. Social defeat interacts with Disc1 mutations in the mouse to affect behavior. Behav Brain Res. 2012;233:337-344.
18. Mei L, Xiong WC. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci. 2008;9:437- 452. (Pubitemid 351704944)
19. Kato T, Kasai A, Mizuno M, Fengyi L, Shintani N, Maeda S, et al. Phenotypic characterization of transgenic mice overexpressing neuregulin-1. PLoS One. 2010;5:e14185.
20. Desbonnet L, O'Tuathaigh C, Clarke G, O'Leary C, Petit E, Clarke N, et al. Phenotypic effects of repeated psychosocial stress during adolescence in mice mutant for the schizophrenia risk gene neuregulin-1: a putative model of gene x environment interaction. Brain Behav Immun. 2012;26:660-671.
21. Vuillermot S, Joodmardi E, Perlmann T, Ove Ogren S, Feldon J, Meyer U. Schizophrenia-relevant behaviors in a genetic mouse model of constitutive Nurr1 deficiency. Genes Brain Behav. 2011;10:589-603.
22. Vuillermot S, Joodmardi E, Perlmann T, Ogren SO, Feldon J, Meyer U. Prenatal immune activation interacts with genetic Nurr1 deficiency in the development of attentional impairments. J Neurosci. 2012;32:436-451.
23. Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A, Vaudry H. Pituitary adenylate cyclase-Activating polypeptide and its receptors: from structure to functions. Pharmacol Rev. 2000;52: 269-324. (Pubitemid 30368434)
24. Hashimoto R, Hashimoto H, Shintani N, Chiba S, Hattori S, Okada T, et al. Pituitary adenylate cyclase-Activating polypeptide is associated with schizophrenia. Mol Psychiatry. 2007;12: 1026-1032. (Pubitemid 350006203)
25. Fone KC, Porkess MV. Behavioural and neurochemical effects of post-weaning social isolation in rodents-relevance to developmental neuropsychiatric disorders. Neurosci Biobehav Rev. 2008;32:1087-1102.
26. Ishihama T, Ago Y, Shintani N, Hashimoto H, Baba A, Takuma K, et al. Environmental factors during early developmental period influence psychobehavioral abnormalities in adult PACAP-deficient mice. Behav Brain Res. 2010;209:274-280.
27. Swartz MS, Swanson JW, Hannon MJ. Detection of illicit substance use among persons with schizophrenia by radioimmunoassay of hair. Psychiatr Serv. 2003;54:891-895. (Pubitemid 36629102)
28. Nabeshima T, Mouri A, Murai R, Noda Y. Animal model of schizophrenia: dysfunction of NMDA receptor-signaling in mice following withdrawal from repeated administration of phencyclidine. Ann N Y Acad Sci. 2006;1086:160-168. (Pubitemid 47084371)
29. Mouri A, Noda Y, Enomoto T, Nabeshima T. Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment. Neurochem Int. 2007;51:173-184. (Pubitemid 47176714)
30. Prata DP, Mechelli A, Fu CH, Picchioni M, Toulopoulou T, Bramon E, et al. Epistasis between the DAT 3′ UTR VNTR and the COMT Val158Met SNP on cortical function in healthy subjects and patients with schizophrenia. Proc Natl Acad Sci U S A. 2009;106:13600-13605.
31. Kirby BP, Waddington JL, O'Tuathaigh CM. Advancing a functional genomics for schizophrenia: psychopathological and cognitive phenotypes in mutants with gene disruption. Brain Res Bull. 2010;83:162-176.
32. Maynard TM, Sikich L, Lieberman JA, LaMantia AS. Neural development, cell-cell signaling, and the "two-hit" hypothesis of schizophrenia. Schizophr Bull. 2001;27:457-476. (Pubitemid 33081697)